Understanding Tysabri PML Risk: Dose and Duration Patterns

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Occupational Exposure Concerns

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This risk is closely tied to the dose and duration of treatment, with longer exposure and higher cumulative doses increasing the likelihood of PML. Building on decades of pharmacovigilance research, this page provides a clear comparison of symptom patterns and clinical signals associated with Tysabri-related PML.

Understanding Tysabri and Its Association with Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning further notes that risk factors for developing PML include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefit when initiating and continuing Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable but typically includes subacute onset of neurologic deficits such as cognitive impairment, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Because PML can progress rapidly, early recognition is critical. The prescribing information instructs healthcare professionals to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first such sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML Development and Adverse Event Reports

The mechanistic pathway linking Tysabri to PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs normal immune surveillance of the brain. In patients who harbor latent JCV, the reduced immune surveillance can allow the virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients who are anti-JCV antibody positive, have been on Tysabri for more than two years, or have previously used immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) for Tysabri frequently include neurologic and systemic symptoms that may overlap with early PML manifestations. The most commonly reported events include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the importance of distinguishing PML from multiple sclerosis relapse or other neurologic conditions in Tysabri-treated patients.

Risk Communication and the TOUCH Prescribing Program

From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central consideration. The boxed warning is prominently displayed in the prescribing information and clearly states the increased risk of PML, the associated risk factors, and the requirement for monitoring. Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which mandates that prescribers, patients, and pharmacies enroll and comply with specific monitoring and reporting requirements. Under this program, patients must be evaluated three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri. Healthcare providers must determine every six months whether patients should continue treatment and must submit status reports to Biogen. Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and prescribers were adequately informed of the risk, particularly in the early years of Tysabri use or in cases where monitoring was not performed as recommended.

Statute of Limitations for Tysabri-Related PML Claims in Texas

For affected patients in Texas, attorney-related considerations include the statute of limitations for filing a product liability or personal injury lawsuit. In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For PML associated with Tysabri, the timeline between exposure and documented harm can be variable. PML may develop months to years after starting Tysabri, and the diagnosis may be delayed due to the similarity of symptoms to multiple sclerosis relapse. The discovery rule may apply, meaning the statute of limitations may begin when the patient knew or reasonably should have known that the injury was caused by Tysabri. Given the complexity of medical causation and the need to establish when the injury was discovered, patients should consult with an attorney experienced in pharmaceutical litigation to assess their individual circumstances and ensure timely filing. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and monitoring requirements outlined in its prescribing information. The clinical presentation of PML can be subtle and may mimic other neurologic conditions, making early diagnosis challenging. For patients in Texas who have developed PML after Tysabri use, legal considerations include the statute of limitations, which may be affected by the timing of diagnosis and discovery of the link to the drug. A thorough review of the medical record and consultation with legal counsel are essential steps for affected individuals.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Texas?

In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For PML associated with Tysabri, the discovery rule may apply, meaning the clock may start when the patient knew or reasonably should have known that the injury was caused by Tysabri. Given the complexity, consulting an attorney is crucial.

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefit when initiating and continuing Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.